AzurRx BioPharma Cultura da Companhia

Mr. Maged S. Shenouda, R.Ph, MBA has been the Chief Financial Officer and Executive Vice-President of AzurRx BioPharma, Inc. since September 25, 2017. Mr. Shenouda served as a Management Consultant at Price Waterhouse, focusing on the pharmaceutical industry. Mr. Shenouda has over 25 years of biotechnology and equity research experience. He was the Head of Business Development and Licensing at Retrophin, Inc from January 2014 to November 2014. Mr. Shenouda, a financial professional in the biotechnology industry, was the head of Business Development at Retrofin, Inc. from January 2014 to November 2014. Prior to that, he served as the Managing Director and Head of East Coast Operations at Blueprint Life Science Group From January 2012 to September 2013. He worked as a hospital representative and managed care specialist for Abbott Laboratories' Pharmaceutical Products Division. Mr. Shenouda was a financial analyst, first at UBS from January 2004 to March 2010 and Stifel Nicolaus from June 2010 to November 2011. He was Managing Director at Stifel, Nicolaus & Company, Incorporated, Research Division. He was in the healthcare group of Stifel Nicolaus Equity Research, specializing in the coverage of biotechnology companies. An Analyst since 1999, he joined Stifel in July 2010 from UBS Investment Bank, Research Division, where he was a Biotechnology Analyst since 2004. He worked as a Biotechnology Analyst at JP Morgan Chase & Co, Research Division from 2000 to 2004. Prior to that, Mr. Shenouda was a Biotechnology and European Pharmaceuticals Analyst at Bear Stearns Companies Inc., Research Division and as an Associate Pharmaceuticals Analyst at Salomon Smith Barney. He started his sell-side career with Citigroup and Bear Stearns where his coverage universe focused on U.S and European pharmaceutical companies. Before beginning his career on Wall Street, Mr. Shenouda was a management consultant with PricewaterhouseCoopers Pharmaceutical Consulting. He has been an Independent Director of Relmada Therapeutics, Inc. since November 12, 2015. He has been a Director of AzurRx BioPharma, Inc. since October 2015. He served as an Independent Director of Protea Biosciences Group, Inc from April 17, 2015 to June 9, 2017. Mr. Shenouda holds an MBA in Marketing from Rutgers University and a BS in Pharmacy from St. John's University's College of Pharmacy. He is a registered pharmacist in New Jersey and California.

Mr. Martin Krusin serves as Vice President of Finance and Business Development at AzurRx BioPharma, Inc. Mr. Krusin is an experienced executive with over 15 years of business development, strategic marketing, financing and operating experience in the healthcare, financial services and consulting sectors. Prior to joining AzurRx BioPharma as Vice President for Business Development in 2012, Mr. Krusin served as Director of Business Development at Clewed (a business services and investment partnership); an Experienced Commercial Leader at GE Capital in its Global Sponsor Finance, Healthcare Financial Services and Capital Solutions units; Vice President of Marketing & Sales and Director of Business Development at Electro-Optical Sciences (now MelaSciences); and an analyst in the Emerging Markets Strategic Planning Group at Citigroup. Mr. Krusin received an MBA from Columbia Business School in finance and marketing, a MPhil. in political economy from Oxford University and a BA in International Relations from Swarthmore College.

Mr. Daniel Dupret has been the Chief Scientific Officer of AzurRx BioPharma, Inc. since June 2016. Mr. Dupret joined AzurRx BioPharma after serving as President of ProteaBio Europe, a wholly-owned European subsidiary of Protea Biosciences. He joined Protea Biosciences in October 2008 to launch and manage ProteaBio Europe. Previously, he founded Prot???us SA in 1998 and served as its President and Chief Executive Officer from 1998 to 2007. Mr. Dupret has spent his entire professional career in the biotechnology industry. He joined Pierre Chambon's lab in Strasbourg, France. His investigation were concerning the evolution of the repeated sequences of the ovomucoid and ovotransferrin genes. In 1981, he joined Transgene, Strasbourg, France, as a Project Leader. His group worked on the cloning and the expression of alpha and beta interferons. He established the laboratories for fermentation and recombinant protein purification at Transgene. In 1985, he founded Appligene SA. He was Scientific Director(CSO), Chief Executive Officer and President of Appligene until 1997. From 1993 to 1995, he initiated a research program for fine DNA structure analysis. From 1982 to 1985, he served as Project Leader at Transgene SA. In parallel to his Biotechnology career, Mr. Dupret was an expert for the French government and the European commission in grant commission and funding of young biotech companies. He serves as the Chairman of l'Ecole de l'ADN. From 2003 to 2007, he served as President of the Board of the University of N???mes. He has been a member of the committee 'Life fronteers: toward French-style biomedical ethics. He has been one of the authors of the final report published at the Documentation Fran???aise. In 1989, he introduced the DNA fingerprinting technique in France where it has been applied for the first time in criminal affairs. He has been advisor to the Toxicology and Forensic Science Laboratory of Paris, France for genetic fingerprinting and has been EC-expert for biotechnology (European Commission, DG XII). He became an Engineer in biochemistry at the INSA, Lyon, France.

Maged Shenouda serves as the Chief Financial Officer for AzurRx BioPharma, Inc.. Maged started at AzurRx BioPharma, Inc. in September of 2017. Maged is based in the Greater New York City Area.